scholarly journals Insulin-Like Growth Factor I Is Not a Useful Marker of Prostate Cancer in Men with Elevated Levels of Prostate-Specific Antigen1

2000 ◽  
Vol 85 (8) ◽  
pp. 2744-2747
Author(s):  
Patrik Finne ◽  
Anssi Auvinen ◽  
Hannu Koistinen ◽  
Wan-Ming Zhang ◽  
Liisa Määttänen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Cancer Risk ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Elevated Serum ◽  
Prostate Cancer Risk ◽  
Factor I ◽  
Igf I ◽  
Igfbp 3

High serum levels of insulin-like growth factor I (IGF-I) and low levels of IGF-binding protein-3 (IGFBP-3) have been shown to correlate with increased prostate cancer risk. To evaluate this, IGF-I, IGFBP-3, and prostate-specific antigen (PSA) were measured in serum from 665 consecutive men (179 with prostate cancer), aged 55–67 yr, with elevated serum prostate-specific antigen (PSA; ≥4 μg/L) in a screening trial. Men in the highest quartile of IGF-I levels had an odds ratio (OR) for prostate cancer of 0.50 [95% confidence interval (CI) 0.26–0.97] when adjusting for serum IGFBP-3. IGFBP-3 itself was not significantly associated with prostate cancer risk (OR, 1.24; 95% CI, 0.68–2.24). Prostate volume was larger in men without than in those with prostate cancer (P < 0.001), and after adjustment for prostate volume, the negative association between serum IGF-I and prostate cancer risk was no longer significant (OR, 0.57; 95% CI, 0.28–1.16). In screen-positive men with elevated serum PSA, serum IGF-I is not a useful diagnostic test for prostate cancer, but it may be associated with benign prostatic hyperplasia and enlargement.

High Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate Cancer Risk: A Prospective Study in a Population-Based Nonscreened Cohort

2004 ◽  
Vol 22 (15) ◽  
pp. 3104-3112 ◽  
Author(s):  
Pär Stattin ◽  
Sabina Rinaldi ◽  
Carine Biessy ◽  
Ulf-Håkan Stenman ◽  
Göran Hallmans ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Population Based ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Bottom Quartile ◽  
Igf I ◽  
Igfbp 3

PurposeInsulin-like growth factor-I (IGF-I) stimulates proliferation and inhibits apoptosis in prostate cancer cells, and IGF-I has been associated with increased prostate cancer risk in some, but not all, epidemiologic studies.Subjects and MethodsWe extended our previous case-control study nested in the Northern Sweden Health and Disease Cohort, a population-based cohort from a region where little prostate specific antigen (PSA) screening is done. Levels of IGF-I and IGF binding protein-3 (IGFBP-3) were measured in prediagnostic blood samples from a total of 281 men who were subsequently diagnosed with prostate cancer after recruitment (median, 5 years after blood collection) and from 560 matched controls.ResultsLogistic regression analyses showed increases in prostate cancer risk with increasing plasma peptide levels, up to an odds ratio (OR) for top versus bottom quartile of IGF-I of 1.67 (95% CI, 1.02 to 2.71; Ptrend= .05), which was attenuated after adjustment for IGFBP-3 to an OR of 1.47 (95% CI, 0.81 to 2.64; Ptrend= .32). For men younger than 59 years at recruitment, OR for top versus bottom quartile of IGF-I was 4.12 (95% CI, 1.01 to 16.70; Ptrend= .002), which was significantly stronger than for men older than 59 years (Pinteraction= .006). For men with advanced cancer, OR for top versus bottom quartile of IGF-I was 2.87 (95% CI, 1.01 to 8.12; Ptrend= .10).ConclusionOur data add further support for IGF-I as an etiologic factor in prostate cancer and indicate that circulating IGF-I levels measured at a comparatively young age may be most strongly associated with prostate cancer risk.

Are plasma Insulin-Like Growth Factor I (IGF-I) and Igf-Binding Protein 3 (Igfbp-3) Useful Markers of Prostate Cancer?

2004 ◽  
Vol 19 (2) ◽  
pp. 164-167 ◽  
Author(s):  
J.B. Lopez ◽  
R.M. Sahabudin ◽  
L.P. Chin
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Binding Protein ◽  
Specific Antigen ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Igf I ◽  
The Mean ◽  
Growth Factor I ◽  
Igfbp 3

Increased concentrations of insulin-like growth factor I (IGF-I) and decreased insulin-like growth factor binding protein 3 (IGFBP-3) in serum have been proposed as markers of prostate cancer (CaP). The evidence for this, however, is contradictory. We assayed serum for IGF-I, IGFBP-3 and prostate-specific antigen (PSA) in patients with CaP and benign prostatic hyperplasia (BPH) and in healthy controls (HC). The mean ± SD concentration of IGF-I in CaP (98.3 ± 39.3 ng/mL; n=15) was lower than in BPH (119 ± 31.1 ng/mL; n=24) and HC (119 ± 36.1 ng/mL; n=46), but the differences between the three groups were not statistically significant (p>0.05). The mean IGFBP-3 concentrations in CaP (2691 ± 1105 ng/mL; n=16; p=0.029) and BPH (2618 ± 816 ng/mL; n= 26; p=0.006) patients were significantly lower than that of the HC (3119 ± 618 ng/mL; n=59), but the difference between the two groups of patients was not significant (p>0.05). PSA concentrations in CaP (median=80.8 ng/mL; n=25) were significantly higher than those in BPH (median=8.6 ng/mL; n=39) (p<0.001). Ninety-six percent of CaP and 72% of BPH patients had PSA concentrations >4.0 ng/mL; the proportions of patients with concentrations exceeding 20 ng/mL were 76% and 10%, respectively. We conclude that IGF-I and IGFBP-3 are inferior to PSA for CaP detection.

scholarly journals IGF-I, insulin and prostate cancer

2009 ◽  
Vol 53 (8) ◽  
pp. 969-975 ◽  
Author(s):  
Giovanna A. Balarini Lima ◽  
Lívia L. Corrêa ◽  
Rafael Gabrich ◽  
Luiz Carlos D. de Miranda ◽  
Mônica R. Gadelha
Keyword(s):  
Prostate Cancer ◽  
Growth Factors ◽  
Cancer Risk ◽  
Cancer Cells ◽  
Growth Regulation ◽  
Specific Antigen ◽  
Prostate Cancer Risk ◽  
Adult Men ◽  
Igf I ◽  
High Insulin

Prostate cancer is the second most frequent malignancy diagnosed in adult men. Androgens are considered the primary growth factors for prostate normal and cancer cells. However, other non-androgenic growth factors are involved in the growth regulation of prostate cancer cells. The association between IGF-I and prostate cancer risk is well established. However, there is no evidence that the measurement of IGF-I enhances the specificity of prostate cancer detection beyond that achievable by serum prostate-specific antigen (PSA) levels. Until now, there is no consensus on the possible association between IGFBP-3 and prostate cancer risk. Although not well established, it seems that high insulin levels are particularly associated with risk of aggressive prostatic tumours. This review describes the physiopathological basis, epidemiological evidence, and animal models that support the association of the IGFs family and insulin with prostate cancer. It also describes the potential therapies targeting these growth factors that, in the future, can be used to treat patients with prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document